Brief: MyMD Pharmaceuticals Provides Dosing Update On Phase 2 Multi-Center Clinical Trial Of MYMD-1
Brief: MyMD Pharmaceuticals Receives Grant From European Patent Office For Supera-CBD Compound
Brief: MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial Of MYMD-1 As Therapy For Delaying Aging And Extending Healthy Lifespan
Brief: Mymd Pharmaceuticals To Collaborate With Bascom Palmer Eye Institute To Study Mymd-1 In Ophthalmic Conditions
Brief: Mymd Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial Of Mymd-1
Brief: MyMD Pharma's Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in Preclinical Model
Brief: MyMD Pharmaceuticals Enrolls First Patient In Phase 2 Clinical Trial Of MYMD-1 As Therapy For Delaying Aging And Extending Healthy Lifespan
Brief: Mymd Pharmaceuticals Announces Positive Clinical Data In Advance Of Upcoming Phase 2 Trial Of Mymd-1 For Extending Healthy Lifespan
Brief: Mymd Pharmaceuticals Announces Issuance Of New U.S. Patent Covering Mymd-1 In A Method Of Treating Sarcopenia
Oramed rises as subsidiary signs pre-purchase order for COVID-19 vaccine
Brief: Mymd Pharmaceuticals Investment Company Oravax Medical Signs Cooperation And Purchase Agreement For Initial Pre-Purchase Of 10 Million Doses Of Oral Covid-19 Vaccine To Be Commercialized In Southeast Asia
Brief: MyMD Pharma Announces Issuance Of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan
Brief: MyMD Pharma Investment Company Oravax Medical And Genomma Lab Announce Joint Venture
Brief: MyMD Pharmaceuticals Receives FDA Ind Clearance To Begin Phase 2 Trial Of MYMD-1
Brief: MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency Of Novel Synthetic Supera-Cbd Over Plant-Derived Cbd
Brief: MyMD Pharmaceuticals Announces Issuance Of U.S. Patent For Use Of Lead Candidate Mymd-1 For Treating Fibrosis And Asthma
Brief: Mymd Pharmaceuticals Subsidiary Oravax Medical Preparing To Commence Clinical Trials For Oral Covid-19 Vaccine
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:30 AM
NASDAQ RESUMED AT 10:35 AM